imSAVAR

Immune safety avatar: nonclinical mimicking of the immune system effects of immunomodulatory therapies

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 15
Grant agreement number
853988

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
10 999 316
EFPIA in kind
11 246 496
Associated Partners
105 000
Total Cost
22 350 812

Summary

Certain treatments for cancers and autoimmune diseases work by altering the immune system. However, a major challenge for researchers is identifying potential efficacy and safety issues with these treatments early in drug development, before they are tested in humans. Part of the problem is that the tests used early in drug development do not reflect the full complexity of the human immune system. In addition, these tests tend to be based on a healthy immune system, which is different to the immune system of someone who is ill.

The imSAVAR project aims to deliver a range of tools that will enhance our ability to assess the efficacy and safety of these immunomodulatory therapies. They also plan to develop new biological markers for diagnosing and predicting immune-mediated safety issues, and explore ways of mitigating them.

In the longer term, the project will help to deliver safer medicines for patients and also contribute to the ‘3Rs’ (i.e. the drive to replace, reduce and refine the use of animals in research).

Participants Show participants on map

EFPIA companies
  • Bluebird Bio Inc., Cambridge Ma, United States
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Covance Laboratories LTD, Harrogate, United Kingdom
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Institut De Recherches Servier, Suresnes, France
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Transgene SA, Illkirch-Graffenstaden, France
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Bundesinstitut Fur Impfstoffe Und Biomedizinische Arzneimittel, Langen, Germany
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V., München, Germany
  • Lunds Universitet, Lund, Sweden
  • Medizinische Hochschule Hannover, Hannover, Germany
  • Medizinische Universitat Innsbruck, Innsbruck, Austria
  • Universitaet Leipzig, Leipzig, Germany
  • Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • Universiteit Twente, Enschede, Netherlands
  • Universitetet I Oslo, Oslo, Norway
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biosci Consulting Bvba, Maasmechelen, Belgium
  • Dynamic42 GMBH, Jena, Germany
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
  • T-Curx GMBH, Wurzburg, Germany
  • Universitätsklinikum Jena, Jena, Germany
Associated partners
  • Jdrf International, New York, United States

CONTACT

Project coordinator
Ulrike Köhl
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
ulrike.koehl[at]izi.fraunhofer.de